We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Scancell Holdings Plc | LSE:SCLP | London | Ordinary Share | GB00B63D3314 | ORD 0.1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | |
|---|---|---|---|---|---|
| -0.15 | -1.53% | 9.65 | 9.50 | 9.80 |
| High Price | Low Price | Open Price | Shares Traded | Last Trade |
|---|---|---|---|---|
| 9.80 | 9.65 | 9.80 | 2,806,417 | 09:22:57 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 0 | -5.86M | -0.0057 | -16.93 | 101.6M |
| Date | Time | Source | Headline |
|---|---|---|---|
| 09/1/2025 | 11:43 | ALNC |  Scancell encouraged by early results in cancer vaccine trial |
| 09/1/2025 | 07:00 | UK RNS | Scancell Holdings Plc Modi-1 Vaccine Achieves Early Clinical Validation |
| 09/12/2024 | 11:41 | UK RNS | Scancell Holdings Plc Result of Retail Offer and Total Voting Rights |
| 06/12/2024 | 12:11 | ALNC | IN BRIEF: Scancell funded deep into 2026 as raises GBP10 million |
| 05/12/2024 | 12:39 | UK RNS | Scancell Holdings Plc Result of Placing and Subscription |
| 04/12/2024 | 18:03 | UK RNS | Scancell Holdings Plc Retail Offer for up to £1 million |
| 04/12/2024 | 17:59 | UK RNS | Scancell Holdings Plc Proposed fundraise in excess of £8.5 million |
| 04/12/2024 | 07:00 | UK RNS | Scancell Holdings Plc Second Commercial License Agreement with Genmab |
| 18/11/2024 | 15:55 | ALNC | Scancell announces promising findings from cancer drug trial |
| 18/11/2024 | 07:00 | UK RNS | Scancell Holdings Plc Positive data from Phase 2 SCOPE trial with SCIB1 |
1 Year Scancell Chart |
Intraday Scancell Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
